CRISPR & Genetic Engineering News and Discussions

weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

1st UK child to receive gene therapy for fatal genetic disorder is now 'happy and healthy'
By Nicoletta Lanese
published about 23 hours ago
https://www.livescience.com/1st-uk-chil ... nd-healthy
A baby with a rare inherited disorder became the first child in the U.K. to receive a new gene therapy for the condition.

A 19-month-old girl named Teddi recently became the first child in the U.K. outside a clinical trial to receive a new gene therapy for metachromatic leukodystrophy (MLD), a fatal genetic disorder, the National Health Service (NHS) announced (opens in new tab).

Roughly six months out from treatment, "Teddi is a happy and healthy toddler showing no signs of the devastating disease she was born with," the NHS statement reads.

The genetic disorder MLD disrupts cells' ability to break down sulfatides, a fatty material used to insulate the wiring that runs through the white matter of the brain and much of the nervous system beyond the brain. Sulfatide buildup destroys brain and nerve cells, resulting in cognitive problems, a loss of motor control and sensation, seizures, paralysis and blindness, according to the Genetic and Rare Diseases Information Center (opens in new tab). Eventually, the disorder leads to death.

Typically, MLD treatment is aimed at managing symptoms of the disease, although several experimental therapies, including bone marrow transplants and cord blood stem cell transplants, have sometimes been used to slow the disorder's progression in infants, according to the Centers for Disease Control and Prevention (opens in new tab). The new gene therapy, called Libmeldy (generic name atidarsagene autotemcel), was only recently cleared for use by the NHS and works by inserting into the body working copies of the genes that are faulty in MLD, thus restoring the ability to break down sulfatides.
User avatar
PineappleDuckCurry
Posts: 16
Joined: Sat Dec 31, 2022 7:08 am

Re: CRISPR & Genetic Engineering News and Discussions

Post by PineappleDuckCurry »

Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

More at...

Https://www.technologyreview.com/2023/0 ... rispr/amp/

TLDR: CRISPR could be used to reduce cholesterol or potentially fight diabetes
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

New research explores the rules of CRISPR activation
https://phys.org/news/2023-03-explores-crispr.html
by Wellcome Trust Sanger Institute
New research is starting to write the rulebook on how to effectively use CRISPR activation technology.

Researchers from the Wellcome Sanger Institute and collaborators have used human stem cells and neurons to investigate the features that influence how well CRISPR activation works for different sets of genes.

Published today (March 13, 2023) in Molecular Cell, the study explains the rules determining to what extent genes respond to CRISPR activation, ensuring that future research can be designed as efficiently as possible.

CRISPR activation (CRISPRa) is a type of CRISPR gene editing that is used to overexpress certain genes. Although this technique is broadly used, predicting its efficiency when aimed at certain points in the genome can be challenging, making it hard to reliably overexpress certain genes.

This new study integrated a marker gene at thousands of points in the genome of a human stem cell line, which was then activated with CRISPRa, to see where this was successful. The stem cell line used differentiates into neurons, allowing the team to also gather information on CRISPRa efficiency in different cell types.

The team uncovered multiple features that impact CRISPRa efficiency, including expression level, chromatin status, cell state, and gene location. They found that bivalent genes, which are key developmental regulator genes that have both repressing and activating marks in the same region, can be robustly activated by CRISPRa. They also discovered that CRISPRa could achieve the same overexpression levels that are necessary to drive significant changes in cell state and cause them to differentiate.
User avatar
wjfox
Site Admin
Posts: 8732
Joined: Sat May 15, 2021 6:09 pm
Location: London, UK
Contact:

Re: CRISPR & Genetic Engineering News and Discussions

Post by wjfox »

Commercial development of gene-edited food now legal in England

31 minutes ago

Gene-edited food can now be developed commercially in England following a change in the law.

Supporters of the technology say it will speed up the development of hardier crops that will be needed because of climate change.

Critics say that the change could bring ''disaster'' to our food production and the environment.

Gene editing involves making precise changes to an organism's DNA to enhance certain characteristics.

The new law also opens the door to the development of gene-edited farm animals, but a further vote by MPs will be required before it is allowed, again only in England.

The Scottish, Welsh and Northern Irish governments have not permitted the commercial use of gene editing.

https://www.bbc.co.uk/news/science-environment-64596453


Image
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

Base editing of SMN2 gene restores production of SMN protein, curing spinal muscular atrophy in mice
https://medicalxpress.com/news/2023-03- ... n-smn.html
by Bob Yirka , Medical Xpress

A team of medical researchers affiliated with a host of institutions in the U.S. has used base editing to restore the natural production of the SMN protein in mice, effectively curing spinal muscular atrophy (SMA) in the rodents. In their paper published in the journal Science, the group describes their base editing approach and its performance in restoring natural SMN production in mice afflicted with SMA.

SMA is one of the leading causes of infant mortality in humans. Babies born with the condition have a mutation in the SMN1 gene, resulting in production of insufficient amounts of the protein SMN, leading to neural deterioration and death. Many babies born with the condition who are diagnosed early enough are given drugs to increase production of SMN artificially, which slows progression of the disease, but cannot stop it completely. Thus, other therapies are needed.

In this new effort, the researchers used base editing, a kind of gene editing that is done chemically, to treat the disease in mice. Base editing is typically used to make single-nucleotide changes in a genome, as was done in this case.
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

New nanoparticles deliver gene-editing tech directly into the lungs
By Paul McClure
April 02, 2023
https://newatlas.com/medical/new-nanopa ... tly-lungs/

Developing effective treatments for genetic lung diseases such as cystic fibrosis has proven challenging. That might not be the case for much longer, with scientists developing a new type of nanoparticle that can carry gene-editing technology directly into the lungs of mice.

With the mapping of the human genome and subsequent genome-wide association studies linking defined genetic mutations with known diseases, the focus of much research has been on developing gene therapies to target the genetic causes of disease.

Messenger RNA (mRNA) is a relatively new therapeutic agent being used to prevent and treat certain genetic diseases. But to function effectively in the body, mRNA – which carries the genetic information that directs cells to make proteins – needs a stable delivery system that protects it from degradation and allows it to enter cells to deliver its gene-altering payload. Nanoparticles have proved effective vehicles for delivering mRNA.
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

Research suggests avenues toward gene therapies for polycystic kidney disease

by Yale University
https://medicalxpress.com/news/2023-04- ... idney.html
Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal genetic disease—about a half million people in the United States alone suffer from the condition. There is no cure, but new research could open the door to new gene therapies for treating most cases of the disease.

For several decades, researchers have known that mutations in the PKD1 gene, which encodes the polycystin-1 (PC1) protein, can cause the disease in about 80% of cases. However, the protein is too big to be modified through gene therapy strategies.

Now, a research team led by Laura Onuchic, MD, postdoctoral researcher in the Yale Department of Cellular & Molecular Physiology and Michael Caplan, MD, Ph.D., chair and C.N.H. Long Professor of Cellular & Molecular Physiology and professor of cell biology, has found that just a small piece of this protein might hold the key to preventing the disease. This finding could lead to opportunities to develop a new class of therapeutics. The team published its findings on March 30 in Nature Communications.

"Our research shows that a tiny fragment of the PC1 protein—just 200 amino acids from the very tail end of that protein—is enough to suppress the disease in a mouse model," says Caplan, who was principal investigator of the study. "Our work will provide new insights into the underlying disease mechanisms for polycystic kidney disease and reveal new avenues for developing therapies."
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

Fewer Unwanted Mutations – New Technique Opens the Door to Safer Gene Editing
https://scitechdaily.com/fewer-unwanted ... e-editing/
By Nagoya University April 14, 2023

Abstract Gene Editing
Researchers from Kyushu University and Nagoya University School of Medicine have developed an optimized genome-editing method that significantly reduces unwanted mutations and toxicity in CRISPR-Cas9. The new technique, called “safeguard gRNA” ([C]gRNA), demonstrates potential for safe and efficient gene therapy, with applications in treating genetic diseases like fibrodysplasia ossificans progressiva.
CRISPR-Cas9 is a prevalent genome-editing technique utilized for investigating specific genes and modifying genes related to diseases. However, it comes with drawbacks such as unintended mutations and toxicity, necessitating the development of a technology that minimizes these side effects to enhance its applicability in industry and medicine.

Scientists from Kyushu University in southern Japan and Nagoya University School of Medicine in central Japan have now created an enhanced genome-editing approach that significantly reduces mutations, paving the way for more effective treatment of genetic disorders with reduced undesired mutations. Their research has been published in Nature Biomedical Engineering.
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

New gene therapy lowers eye pressure to treat glaucoma
By Paul McClure
April 20, 2023
https://newatlas.com/medical/new-gene-t ... -glaucoma/
The high eye pressure seen in glaucoma slowly leads to blindness. For some, the first-line treatment, eye drops, doesn’t work. Researchers have used gene therapy to develop a promising new way of treating the high eye pressure associated with glaucoma.

Affecting up to 80 million people worldwide, glaucoma is usually caused by raised intraocular pressure (IOP). The number of people with glaucoma is expected to rise to 110 million by 2040.

The eye constantly produces a liquid called aqueous humor, which helps the eye hold its shape and nourishes the eye. The fluid is drained out of the eye through the anterior chamber angle or drainage angle. If the drainage angle is damaged, the eye produces more aqueous humor than it can drain, causing high IOP that can irreversibly damage the optic nerve, leading to blindness.

The first-line treatment for glaucoma is eye drops made of a prostaglandin analog, which lowers IOP. However, 25% to 50% of people don’t respond to the treatment, and their eye pressure remains elevated.

Researchers at Trinity College Dublin have collaborated with the biotechnology company Exhaura Ltd to develop a novel gene-therapy-based approach to decreasing IOP that shows great promise in the treatment of glaucoma.

“This exciting project allowed us to bridge the gap between academia and industry and work very closely with a gene therapy company to develop a cutting-edge therapy that we believe holds immense promise for patients in the future,” said Matthew Campbell, corresponding author of the study.
weatheriscool
Posts: 12955
Joined: Sun May 16, 2021 6:16 pm

Re: CRISPR & Genetic Engineering News and Discussions

Post by weatheriscool »

Improved gene editing method could power the next generation of cell and gene therapies
https://phys.org/news/2023-04-gene-meth ... -cell.html
by Perelman School of Medicine at the University of Pennsylvania
A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods. The approach could also power the development of advanced cell therapies for cancers and other diseases, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

In the study, which appeared this week in Nature Biotechnology, researchers found that protein fragments used by some viruses to help them get into cells could also be used to get CRISPR-Cas gene editing molecules into cells and their DNA-containing nuclei with extraordinarily high efficiency and low cellular toxicity.

The scientists expect the new technique to be particularly useful for modifying T cells and other cells from a patient's own body to make cell therapies. One such application could be CAR T (chimeric antigen receptor T cell) therapy, which uses specially modified immune cells from a patient to treat cancer. The T cells—a type of white blood cell—are removed from the patient and reprogrammed to find and attack cancer cells when reintroduced to the bloodstream.

The first FDA-approved CAR T therapy was developed at Penn Medicine, and received Food & Drug Administration approval in 2017. There are now six FDA-approved CAR T cell therapies in the United States. The therapies have revolutionized the treatment of certain B cell leukemias, lymphomas, and other blood cancers, putting many patients who otherwise had little hope into long-term remission.

"This new approach—building on Penn Medicine's history of cell and gene therapy innovation—has the potential to be a major enabling technology for engineered cellular therapies," said co-senior author E. John Wherry, Ph.D., Richard and Barbara Schiffrin President's Distinguished Professor and chair of Systems Pharmacology & Translational Therapeutics at Penn Medicine.

CRISPR-Cas molecules are derived from ancient bacterial antiviral defenses, and are designed to precisely remove DNA at desired locations in a cell's genome. Some CRISPR-Cas-based systems combine the deletion of old DNA with the insertion of new DNA for versatile genome editing. This approach can be used to replace faulty genes with corrected ones or delete or modify genes to enhance cellular function. Some systems can also add genes that confer new properties to CAR T cells such as the ability to recognize tumors or withstand the harsh tumor microenvironment that normally exhausts T cells.
Post Reply